WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Israel
  • Latin America
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • Decarbonization Strategies
  • Energy Regulation and Competition
  • Project Development and Transactions
  • Project Finance and Tax Equity
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security
  • Payments
  • Strategic Risk and Crisis Management

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Merger Clearance
  • Antitrust Litigation
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • FoodTech and AgTech
  • Fintech and Financial Services
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Pro Bono
  • Community
  • Our Diversity
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Beijing
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students + Recent Graduates
  • Experienced Attorneys
  • Patent Agents
  • Professional Staff
  • Alternative Legal Careers
  • Contact Recruiting

Life SciencesLeadership.

Wilson Sonsini has worked with leading life sciences innovators across every industry sector—from biotechnology and diagnostics to medical devices and therapeutics.

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us
Quick Links
  • Visit our Careers Microsite
  • Find the right attorney
  • Sign in to Neuron

When Foresight Diagnostics needed to support the development and commercialization of its technology, Wilson Sonsini delivered.

Check Out Our Case Study
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

  • Attorney Recruiting
  • Professional Staff
  • Contacts

News and Featured Insights

Alerts
The Inflation Reduction Act’s Medicare Price Negotiation Program: Two Years Later
Alerts
DEA and HHS Extend COVID-19 Telemedicine Prescribing Flexibilities Again
Newsletters
European Antitrust Bimonthly Bulletin – September/October 2024
Leading Matters
Client Highlights
Wilson Sonsini Advises Investors on Zenflow’s $24 Million Series C Financing
On November 18, 2024, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), announced that it has closed a $24 million Series C financing round. The round included new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Wilson Sonsini Goodrich & Rosati advised Invus, F-Prime, and MedTech Venture Partners on the transaction.

The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.

The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.

For more information, please see Zenflow’s news release.
Learn More
Client Highlights
Wilson Sonsini Advises Upstart in Private Offering of $500 Million of Convertible Senior Notes
On November 15, 2024, Upstart Holdings, Inc. completed an offering of $500 million aggregate principal amount of 1.00% convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Upstart had granted to the initial purchasers to purchase up to an additional $75 million of notes. 
Learn More
Client Highlights
Firm Advises LuxWall on IP and Patent Strategy Matters Related to $51 Million Series B
On October 31, 2024, LuxWall, a leader in glass-based transparent insulation solutions to reduce energy consumption and carbon emissions from buildings, announced that it has closed a $51 million Series B funding round led by Climate Investment and Barclays Sustainable Impact Capital. New investors Carbon Equity and The Nature Conservancy participated in the round, alongside existing investors Breakthrough Energy Ventures, Prelude Ventures, 2150, Khosla Ventures, and Baruch Future Ventures. Wilson Sonsini Goodrich & Rosati advised LuxWall on IP and patent strategy in connection with the transaction.

The funding allows LuxWall to scale up production at its newly opened factory in Litchfield, Michigan, which received the support from Michigan Governor Gretchen Whitmer. It will also enable the construction and expansion of a second factory in Detroit, Michigan, as well as the growth of research and development at the R&D Center in Ypsilanti, Michigan.

The Wilson Sonsini team that advised LuxWall on the transaction includes Matt Bresnahan, Maysam Pessian, and Jane Yang.

For more information, please see LuxWall’s news release.
Learn More
Client Highlights
Wilson Sonsini Advises Stepful on $31.5 Million Series B Round
On November 13, 2024, Stepful, a company re-imagining healthcare training for allied health professional jobs, announced it successfully raised $31.5 million in Series B funding. The round was led by Oak HC/FT with participation from Y Combinator, Reach Capital, AlleyCorp, SemperVirens, Company Ventures, Green Sands, ECMC Education Impact Fund, Intermountain Ventures, and Cedar Pine. Wilson Sonsini Goodrich & Rosati represented Stepful in the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises LaNova Medicines on Exclusive Global License with Merck
On November 14, 2024, Merck and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that they entered into an exclusive global license for Merck to develop, manufacture, and commercialize LM-299, a novel investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF) that is currently in Phase 1 clinical trials in China. Wilson Sonsini Goodrich & Rosati advised LaNova on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Centerview Partners as Financial Advisor to Special Committee of Charter Communications
On November 13, 2024, Charter Communications and Liberty Broadband Corporation announced that they have entered into a definitive agreement under which Charter has agreed to acquire Liberty Broadband in an all-stock transaction. Under the terms of the agreement, each holder of Liberty Broadband Series A common stock, Series B common stock, and Series C common stock will receive 0.236 of a share of Charter common stock per share of Liberty Broadband common stock held. Liberty Broadband's principal assets currently consist of approximately 45.6 million common shares of Charter and its subsidiary GCI, Alaska's largest communications provider. Liberty Broadband has agreed to spin off its GCI business prior to the closing of the acquisition of Liberty Broadband by Charter.
Learn More
See More Leading Matters

The Entrepreneurs Report – Q3 2024

The latest issue of The Entrepreneurs Report compiles a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the third quarter of 2024, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. This edition also features a market perspective piece discussing AI start-ups and the venture capital ecosystem going into 2025.

Read More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.